Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Bossuyt V, Provenzano E, Symmans WF, Webster F, Allison KH, Dang C, Gobbi H, Kulka J, Lakhani SR, Moriya T, Quinn CM, Sapino A, Schnitt S, Sibbering DM, Slodkowska E, Yang W, Tan PH, Ellis I. Bossuyt V, et al. Histopathology. 2024 Jun;84(7):1111-1129. doi: 10.1111/his.15165. Epub 2024 Mar 5. Histopathology. 2024. PMID: 38443320
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Ho AY, Shiao S, Kobald SA, Chen J, Duda DG, Ly A, Bossuyt V, Cho HL, Arnold B, Knott S, Gupta GP, McAndrew P, Karlan S, Tighiouart M, Muzikansky A, Basho R, McArthur H. Ho AY, et al. Among authors: bossuyt v. J Clin Oncol. 2024 Dec 20;42(36):4282-4293. doi: 10.1200/JCO.24.00003. Epub 2024 Sep 19. J Clin Oncol. 2024. PMID: 39298718 Clinical Trial.
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW. Bardia A, et al. Among authors: bossuyt v. Clin Cancer Res. 2024 Jul 15;30(14):2917-2924. doi: 10.1158/1078-0432.CCR-24-0428. Clin Cancer Res. 2024. PMID: 38709212 Free PMC article. Clinical Trial.
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Spring LM, et al. Among authors: bossuyt v. Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12. Ann Oncol. 2024. PMID: 38092228
Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.
Nishida J, Cristea S, Bodapati S, Puleo J, Bai G, Patel A, Hughes M, Snow C, Borges V, Ruddy KJ, Collins LC, Feeney AM, Slowik K, Bossuyt V, Dillon D, Lin NU, Partridge AH, Michor F, Polyak K. Nishida J, et al. Among authors: bossuyt v. Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2316763120. doi: 10.1073/pnas.2316763120. Epub 2023 Nov 27. Proc Natl Acad Sci U S A. 2023. PMID: 38011567 Free PMC article.
Metaplastic breast cancer: A review.
Thomas HR, Hu B, Boyraz B, Johnson A, Bossuyt VI, Spring L, Jimenez RB. Thomas HR, et al. Among authors: bossuyt vi. Crit Rev Oncol Hematol. 2023 Feb;182:103924. doi: 10.1016/j.critrevonc.2023.103924. Epub 2023 Jan 22. Crit Rev Oncol Hematol. 2023. PMID: 36696934 Review.
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. Zhang M, et al. Among authors: bossuyt v. Sci Transl Med. 2022 Feb 2;14(630):eabf5473. doi: 10.1126/scitranslmed.abf5473. Epub 2022 Feb 2. Sci Transl Med. 2022. PMID: 35108062 Free PMC article.
59 results